DE60119552T2 - Isolierte peptide, die an hla-c moleküle binden und deren verwendung - Google Patents
Isolierte peptide, die an hla-c moleküle binden und deren verwendung Download PDFInfo
- Publication number
- DE60119552T2 DE60119552T2 DE60119552T DE60119552T DE60119552T2 DE 60119552 T2 DE60119552 T2 DE 60119552T2 DE 60119552 T DE60119552 T DE 60119552T DE 60119552 T DE60119552 T DE 60119552T DE 60119552 T2 DE60119552 T2 DE 60119552T2
- Authority
- DE
- Germany
- Prior art keywords
- hla
- cells
- cell
- eso
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 77
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 40
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 title description 17
- 108010052199 HLA-C Antigens Proteins 0.000 title description 7
- 210000004027 cell Anatomy 0.000 claims abstract description 84
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 29
- 108010070768 HLA-C*03 antigen Proteins 0.000 claims abstract description 16
- 108010059045 HLA-C*06 antigen Proteins 0.000 claims abstract description 13
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 17
- 230000005867 T cell response Effects 0.000 claims description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims 6
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 abstract description 6
- 230000001461 cytolytic effect Effects 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 58
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 49
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 48
- 239000000427 antigen Substances 0.000 description 36
- 108091007433 antigens Proteins 0.000 description 36
- 102000036639 antigens Human genes 0.000 description 36
- 239000013598 vector Substances 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 20
- 241000701161 unidentified adenovirus Species 0.000 description 17
- 210000000265 leukocyte Anatomy 0.000 description 16
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 14
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 13
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 description 10
- 241000700618 Vaccinia virus Species 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 6
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 6
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000002703 mutagenesis Methods 0.000 description 5
- 231100000350 mutagenesis Toxicity 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 108700028369 Alleles Proteins 0.000 description 4
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102100029450 M1-specific T cell receptor alpha chain Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 102000011786 HLA-A Antigens Human genes 0.000 description 3
- 108010075704 HLA-A Antigens Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 3
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 3
- 102220519838 Putative neutrophil cytosol factor 1B_P91A_mutation Human genes 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 230000002998 immunogenetic effect Effects 0.000 description 2
- 201000006512 mast cell neoplasm Diseases 0.000 description 2
- 208000006971 mastocytoma Diseases 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000700662 Fowlpox virus Species 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010018475 HLA-A31 antigen Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 102000006390 HLA-B Antigens Human genes 0.000 description 1
- 108010069149 HLA-C*04 antigen Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 102000016200 MART-1 Antigen Human genes 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 101001016849 Mus musculus Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101000985444 Mus musculus Heat shock protein HSP 90-beta Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 1
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007801 sublethal irradiation Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4269—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/670,456 US6506875B1 (en) | 2000-09-26 | 2000-09-26 | Isolated peptides which bind to HLA-C molecules and uses thereof |
| US670456 | 2000-09-26 | ||
| PCT/US2001/029920 WO2002026778A2 (en) | 2000-09-26 | 2001-09-24 | Isolated peptides which bind to hla-c molecules and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60119552D1 DE60119552D1 (de) | 2006-06-14 |
| DE60119552T2 true DE60119552T2 (de) | 2007-04-19 |
Family
ID=24690468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60119552T Expired - Lifetime DE60119552T2 (de) | 2000-09-26 | 2001-09-24 | Isolierte peptide, die an hla-c moleküle binden und deren verwendung |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US6506875B1 (https=) |
| EP (1) | EP1320609B1 (https=) |
| JP (1) | JP4174570B2 (https=) |
| CN (1) | CN1253572C (https=) |
| AT (1) | ATE325876T1 (https=) |
| AU (2) | AU2001293051B2 (https=) |
| CA (1) | CA2423481C (https=) |
| DE (1) | DE60119552T2 (https=) |
| WO (1) | WO2002026778A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7888100B2 (en) * | 1996-10-03 | 2011-02-15 | Memorial Sloan-Kettering Cancer Research | Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein |
| WO2014207708A2 (en) | 2013-06-28 | 2014-12-31 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
| CN105085616A (zh) * | 2014-05-23 | 2015-11-25 | 上海市普陀区中心医院 | 一种氨基酸序列及其应用 |
| CN105085615A (zh) * | 2014-05-23 | 2015-11-25 | 上海市普陀区中心医院 | 一种多肽序列及其应用 |
| BR112017013574A2 (pt) | 2014-12-23 | 2018-03-06 | Verdon Daniel | conjugados de aminoácido e peptídeo e usos dos mesmos |
| EP3419962A4 (en) | 2016-02-26 | 2020-03-11 | Auckland Uniservices Limited | CONJUGATES OF AMINO ACIDS AND PEPTIDES AND CONJUGATION METHOD |
| WO2020178738A1 (en) * | 2019-03-04 | 2020-09-10 | University Health Network | T cell receptors and methods of use thereof |
| MX2021010541A (es) | 2019-03-04 | 2021-12-15 | Univ Health Network | Receptores de linfocitos t y metodos de uso de estos. |
| CN113795586B (zh) | 2019-03-25 | 2026-03-27 | 大学健康网络 | T细胞受体及其使用方法 |
| CN120397921B (zh) * | 2025-05-28 | 2025-12-02 | 江苏新恒鼎装备制造有限公司 | 一种具有自锁功能的船用曲轴红套升降平台 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013481A (en) * | 1993-07-22 | 2000-01-11 | Ludwig Institute For Cancer Research | Isolated, nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof |
| US6251603B1 (en) * | 1996-10-03 | 2001-06-26 | Ludwig Institute For Cancer Research | Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample |
| AU9572098A (en) * | 1997-10-08 | 1999-04-27 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Novel human cancer antigen ny eso-1/cag-3 and gene encoding same |
| JP2002509859A (ja) * | 1998-01-23 | 2002-04-02 | ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ | Ｈｌａ−ａ２９分子に結合する単離ポリペプチド、それらをコードする分子である核酸、およびそれらの使用 |
| WO2000020445A2 (en) * | 1998-10-02 | 2000-04-13 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
| WO2001062917A1 (en) * | 2000-02-22 | 2001-08-30 | Ludwig Institute For Cancer Research | Isolated genomic sequences which encode the ny-eso-1 cancer testis tumor antigen and uses thereof |
-
2000
- 2000-09-26 US US09/670,456 patent/US6506875B1/en not_active Expired - Lifetime
-
2001
- 2001-09-24 CA CA002423481A patent/CA2423481C/en not_active Expired - Fee Related
- 2001-09-24 JP JP2002531161A patent/JP4174570B2/ja not_active Expired - Fee Related
- 2001-09-24 WO PCT/US2001/029920 patent/WO2002026778A2/en not_active Ceased
- 2001-09-24 AU AU2001293051A patent/AU2001293051B2/en not_active Ceased
- 2001-09-24 DE DE60119552T patent/DE60119552T2/de not_active Expired - Lifetime
- 2001-09-24 EP EP01973479A patent/EP1320609B1/en not_active Expired - Lifetime
- 2001-09-24 AU AU9305101A patent/AU9305101A/xx active Pending
- 2001-09-24 CN CNB018194818A patent/CN1253572C/zh not_active Expired - Fee Related
- 2001-09-24 AT AT01973479T patent/ATE325876T1/de active
-
2002
- 2002-10-18 US US10/274,017 patent/US7009035B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP4174570B2 (ja) | 2008-11-05 |
| US7009035B2 (en) | 2006-03-07 |
| CN1253572C (zh) | 2006-04-26 |
| CN1476480A (zh) | 2004-02-18 |
| JP2004524271A (ja) | 2004-08-12 |
| EP1320609B1 (en) | 2006-05-10 |
| US20030050451A1 (en) | 2003-03-13 |
| AU9305101A (en) | 2002-04-08 |
| HK1060594A1 (en) | 2004-08-13 |
| AU2001293051B2 (en) | 2007-04-26 |
| ATE325876T1 (de) | 2006-06-15 |
| EP1320609A2 (en) | 2003-06-25 |
| CA2423481C (en) | 2008-06-10 |
| WO2002026778A3 (en) | 2003-02-13 |
| DE60119552D1 (de) | 2006-06-14 |
| WO2002026778A2 (en) | 2002-04-04 |
| US6506875B1 (en) | 2003-01-14 |
| CA2423481A1 (en) | 2002-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69333670T2 (de) | Vom mage-3-gen abgeleitetes und von hla-a1 präsentiertes, isoliertes nonapeptid und dessen anwendungen | |
| DE69334186T2 (de) | Vom MAGE-3-Gen en abgeleitetes und von HLA-A1 präsentiertes, isoliertes Nonapeptid und dessen Anwendungen | |
| DE69531866T2 (de) | Isoliertes nukleinsäuremolekül, das für den tumorabstossungs-antigenvorläufer dage kodiert und seine verwendung | |
| DE69433518T4 (de) | Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert | |
| US6222012B1 (en) | Isolated nonapeptides presented by HLA molecules, and uses thereof | |
| US5462871A (en) | Isolated nucleic acid molecules which encode MAGE derived nonapeptides | |
| DE69519748T2 (de) | Aus den vorstufen des mage tumor-abstossungsantigen abstammende einzelne peptede, die hla-a2 moleküle komplexieren | |
| DE69520959T2 (de) | Isolierte von tumor abstossenden vorläufer antigen mage-2 abgeleitete peptide und deren verwendung | |
| JPH09502863A (ja) | Ｍｈｃ分子ｈｌａ−ｃ−クローン１０と複合体を形成する分離されたペプチドとその利用方法 | |
| EP1919943B1 (de) | Melanom-assoziierte mhc klasse i assoziierte oligopeptide und deren verwendungen | |
| DE69511399T2 (de) | Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren | |
| DE69931482T2 (de) | Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
| DE60119552T2 (de) | Isolierte peptide, die an hla-c moleküle binden und deren verwendung | |
| DE69329656T2 (de) | Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase-peptidantigenen exprimierenden zellen | |
| DE69838646T2 (de) | Isolierte decapeptide, die an hla moleküle binden, sowie deren verwendung | |
| DE69832875T2 (de) | Isoliertes nukleinsäuremolekül, das die tumorabstossungs-antigenvorläufer mage- c1 und mage-c2 kodiert und seine verwendung | |
| AU2001293051A1 (en) | Isolated peptides which bind to HLA-C molecules and uses thereof | |
| DE10313819A1 (de) | An MHC-Moleküle bindende Tumor-assoziierte Peptide | |
| DE69530410T2 (de) | Methoden zur identifizierung von individuen, die an einer zellulären abnormalität leiden | |
| DE69617255T2 (de) | Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |